Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) jumped 20.7% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts’ constant currency revenue, EPS, and EBITDA expectations. Its quarterly revenue guidance also outperformed Wall Street’s estimates.
The key number was a 30% jump in constant currency sales, led by strong growth in the U.S. and a big push overseas, where Omnipod sales rose 36%. Zooming out, we think this was a solid print.
The shares closed the day at $310.38, up 20.8% from previous close.
Is now the time to buy Insulet? Access our full analysis report here, it’s free.
Insulet’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. But moves this big are rare even for Insulet and indicate this news significantly impacted the market’s perception of the business.
Insulet is up 21.1% since the beginning of the year, and at $311.10 per share, has set a new 52-week high. Investors who bought $1,000 worth of Insulet’s shares 5 years ago would now be looking at an investment worth $1,384.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
